Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax, Inc. (NASDAQ: NVAX) is a biotechnology company focused on vaccines, using a platform that combines protein-based nanoparticles with its proprietary Matrix-M® adjuvant. News about Novavax often centers on its COVID-19 vaccine Nuvaxovid™/Nuvaxovid®, its broader infectious disease pipeline, and the progress of key partnerships and collaborations.
Recent announcements highlight Novavax’s collaboration and license agreement with Sanofi, under which Sanofi has taken on lead commercial and regulatory responsibilities for Nuvaxovid in selected markets. News items cover marketing authorization transfers in the European Union and United States, milestone payments to Novavax, and Sanofi’s clinical data on combination vaccine candidates that incorporate Nuvaxovid and Matrix-M. Updates also describe regulatory approvals in markets such as Japan through partner Takeda, triggering additional milestone payments and royalty opportunities.
Investors following NVAX news will see regular coverage of quarterly financial results, revenue composition from product sales, supply sales and licensing and royalty streams, as well as information on Novavax’s site consolidation and cost footprint in Maryland. The company’s communications also describe early-stage research on vaccine candidates for shingles, Clostridioides difficile colitis and respiratory syncytial virus combinations, and the use of Matrix-M in the R21/Matrix-M malaria vaccine developed with Serum Institute of India and Oxford University.
This page aggregates press releases, conference participation announcements, regulatory updates and other material events related to Novavax. Readers can use it to monitor developments in the company’s vaccine programs, partnership milestones, capital structure transactions and strategic transformation as disclosed in public statements.
On April 13, 2021, Novavax, Inc. (Nasdaq: NVAX) announced key leadership changes, promoting Gale E. Smith, Ph.D., to Senior VP and Chief Scientist, while appointing Troy Morgan as Senior VP and Chief Compliance Officer. Greg Covino will step down as CFO but remain as an executive adviser. Dr. Smith's contributions to Novavax's COVID-19 vaccine candidate and vaccine technology development were highlighted. Morgan brings extensive compliance experience, crucial for Novavax's commercialization strategy. These changes reflect the company's commitment to advancing vaccine solutions against serious infectious diseases.
Novavax (Nasdaq: NVAX), a biotechnology firm, will take part in a fireside chat at the Goldman Sachs virtual conference on April 13, 2021, from 2:30 to 3:20 p.m. ET. The discussion will focus on Novavax's COVID-19 vaccine candidate, NVX-CoV2373, and its implications for the current vaccine landscape. Vivek Shinde, M.D., M.P.H., Vice President of Clinical Development, will represent the company. This event is exclusive to Goldman Sachs clients, highlighting Novavax's ongoing efforts in developing innovative vaccines against serious infectious diseases.
Novavax has initiated crossover arms in its clinical trials for NVX-CoV2373, its COVID-19 vaccine candidate. This allows all participants in the South Africa and UK trials to receive active vaccine doses, ensuring long-term safety and efficacy monitoring. The PREVENT-19 trial in the US and Mexico plans a similar crossover. The trials include a Phase 2b study in South Africa and a pivotal Phase 3 in the UK, with initial data expected in Q2. NVX-CoV2373 boasts a 96.4% efficacy rate against the original virus strain and remains stable at 2°-8°C for distribution.
On April 5, 2021, Novavax (Nasdaq: NVAX) announced that CEO Stanley C. Erck will participate in a panel discussion at the Longwood Healthcare Leaders 2021 Webconference on April 6, 2021. The discussion, titled Progress Towards Sustainable Vaccines for COVID-19, will focus on Novavax's COVID-19 vaccine candidate, NVX-CoV2373. The panel is scheduled for 7:30 – 8:00 a.m. EDT and will be moderated by Harvard's Michael Mina. Novavax is at the forefront of developing innovative vaccines to combat serious infectious diseases, including COVID-19.
Novavax, Inc. (Nasdaq: NVAX) announces a collaboration with GSK and the UK Government to manufacture up to 60 million doses of its COVID-19 vaccine candidate, NVX-CoV2373, starting from May 2021. Under this agreement, GSK will utilize its Barnard Castle facility for 'fill and finish' operations. This partnership aims to bolster the UK's vaccine rollout as over 30 million doses have already been administered. The NVX-CoV2373 vaccine has shown promising efficacy in Phase 3 trials, and regulatory submission is anticipated in the second quarter.
Novavax, Inc. (Nasdaq: NVAX) announced remarkable results from its COVID-19 vaccine, NVX-CoV2373, in pivotal trials. The final analysis of the U.K. Phase 3 trial demonstrated a 96.4% efficacy against the original strain and 89.7% overall efficacy, with 100% protection against severe disease. In South Africa, the Phase 2b trial revealed 55.4% efficacy among HIV-negative participants. Both studies confirmed the vaccine’s effectiveness against variant strains and showed it was well-tolerated. Novavax plans to submit data for regulatory authorization worldwide.
Novavax (Nasdaq: NVAX) announced its participation in a fireside chat at the H.C. Wainwright Virtual Global Life Sciences conference on March 9, 2021. The discussion will focus on Novavax's COVID-19 vaccine candidate, NVX-CoV2373, featuring Dr. Gregory M. Glenn and John Trizzino as speakers. The session will be available on-demand starting at 7:00 a.m. ET. A replay will also be accessible for 90 days on the company’s website.
Novavax specializes in creating next-generation vaccines to combat serious infectious diseases.
Novavax, Inc. (NVAX) announced positive results for its COVID-19 vaccine candidate, NVX-CoV2373, achieving 89.3% efficacy against the original strain in a UK Phase 3 trial. The company completed enrollment of 30,000 participants for the PREVENT-19 trial and secured agreements for 300 million doses, with an additional 1.1 billion doses for COVAX. Financially, Novavax reported a Q4 net loss of $177.6 million, significantly higher than the previous year. Revenue surged to $279.7 million, driven by government contracts. The company has raised over $2 billion in funding to support its vaccine development efforts.
Novavax, Inc. (Nasdaq: NVAX) has announced an exclusive licensing agreement with Takeda Pharmaceutical for the local development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373, in Japan. Takeda has initiated a Phase 2 clinical trial to test the vaccine's immunogenicity and safety in Japanese participants. The partnership aims to produce over 250 million vaccine doses annually and includes milestone payments for Novavax. The company has also reported positive interim results from ongoing clinical trials in the UK.
Novavax, Inc. (Nasdaq: NVAX) has completed the enrollment of 30,000 volunteers for its pivotal Phase 3 PREVENT-19 study, evaluating its COVID-19 vaccine, NVX-CoV2373, across 118 sites in the U.S. and Mexico. The trial aims to demonstrate the vaccine's efficacy, safety, and immunogenicity. Notable diversity was achieved in recruitment, including significant representation from LatinX (20%) and African American (13%) demographics. NVX-CoV2373 is supported by a $1.75 billion U.S. government partnership, focusing on rapidly addressing urgent global health needs.